BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 32476587)

  • 21. Case Report: A Case Report of a Histological Transformation of
    Zhang Y; Qin Y; Xu H; Yao Q; Gao Y; Feng Y; Ren J
    Pathol Oncol Res; 2021; 27():637745. PubMed ID: 34257603
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Alectinib is effective, safe and tolerable in an adolescent with stage IVB ALK-rearranged adenocarcinoma of the lung.
    Balzer BWR; Loo C; Wegner EA; Nath CE; Lee S; Smith C; Lewis CR; Trahair TN; Anazodo AC
    Pediatr Hematol Oncol; 2018; 35(7-8):415-421. PubMed ID: 30526220
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Apatinib reverses alectinib resistance by targeting vascular endothelial growth factor receptor 2 and attenuating the oncogenic signaling pathway in echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase fusion gene-positive lung cancer cell lines.
    Chen Y; Ma G; Su C; Wu P; Wang H; Song X; Yu Q; Zeng A; Zhou S
    Anticancer Drugs; 2018 Nov; 29(10):935-943. PubMed ID: 30074936
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.
    Gadgeel SM; Gandhi L; Riely GJ; Chiappori AA; West HL; Azada MC; Morcos PN; Lee RM; Garcia L; Yu L; Boisserie F; Di Laurenzio L; Golding S; Sato J; Yokoyama S; Tanaka T; Ou SH
    Lancet Oncol; 2014 Sep; 15(10):1119-28. PubMed ID: 25153538
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical characteristics and risk factors of drug-induced lung injury by ALK tyrosine kinase inhibitors: A single center retrospective analysis.
    Koshikawa K; Terada J; Abe M; Iwasawa S; Sakayori M; Yoshioka K; Hirasawa Y; Kasai H; Kawasaki Y; Tsushima K; Tatsumi K
    Thorac Cancer; 2020 Jun; 11(6):1495-1502. PubMed ID: 32237210
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Life-threatening hypertriglyceridemia-induced pancreatitis related to alectinib successfully treated by plasmapheresis: A review of the literature on metabolic toxicities associated with anaplastic lymphoma kinase inhibitors.
    Rao A; Reddy A; Dinunno C; Elali I
    J Oncol Pharm Pract; 2020 Sep; 26(6):1533-1537. PubMed ID: 32054410
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cutaneous sarcoid-like drug reaction caused by an anaplastic lymphoma kinase inhibitor.
    Gleue CA; Shah K; Wentworth A; Bridges A
    J Cutan Pathol; 2021 Mar; 48(3):425-428. PubMed ID: 33128468
    [TBL] [Abstract][Full Text] [Related]  

  • 28. ALK Rearrangement Positive Lung Adenocarcinoma in Pregnancy Treated With Alectinib: A Case Report.
    Gonzalez-Mosquera LF; Rous FA; Rogers A; Smith N; Goyert G; Gadgeel S
    Clin Lung Cancer; 2024 Mar; 25(2):e77-e80. PubMed ID: 38057186
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anaplastic lymphoma kinase inhibitor-associated myositis.
    Uruha A; Kliesch S; Schmid S; Dittmayer C; Goebel HH; Dressel A; Stenzel W; Handreka R
    Neurol Neuroimmunol Neuroinflamm; 2020 Jul; 7(4):. PubMed ID: 32376707
    [No Abstract]   [Full Text] [Related]  

  • 30. Case report: continued treatment with alectinib is possible for patients with lung adenocarcinoma with drug-induced interstitial lung disease.
    Nitawaki T; Sakata Y; Kawamura K; Ichikado K
    BMC Pulm Med; 2017 Dec; 17(1):173. PubMed ID: 29207989
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A patient with ALK-positive lung adenocarcinoma who survived alectinib-refractory postoperative recurrence for 4 years by switching to ceritinib.
    Matsumura Y; Inomata S; Yamaguchi H; Mine H; Takagi H; Watanabe M; Ozaki Y; Yamaura T; Fukuhara M; Muto S; Okabe N; Hasegawa T; Shio Y; Suzuki H
    Thorac Cancer; 2021 Aug; 12(15):2225-2228. PubMed ID: 34159737
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Alectinib for ALK-positive non-small-cell lung cancer.
    Rossi A
    Expert Rev Clin Pharmacol; 2016 Aug; 9(8):1005-13. PubMed ID: 27232673
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety of alectinib for the treatment of metastatic ALK-rearranged non-small cell lung cancer.
    Zhu V; Ou SH
    Expert Opin Drug Saf; 2017 Apr; 16(4):509-514. PubMed ID: 28276856
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Transformation to SCLC after Treatment with the ALK Inhibitor Alectinib.
    Fujita S; Masago K; Katakami N; Yatabe Y
    J Thorac Oncol; 2016 Jun; 11(6):e67-72. PubMed ID: 26751586
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Progression-Free and Overall Survival of Patients With ALK Rearrangement-Positive Non-Small Cell Lung Cancer Treated Sequentially With Crizotinib and Alectinib.
    Watanabe S; Hayashi H; Okamoto K; Fujiwara K; Hasegawa Y; Kaneda H; Tanaka K; Takeda M; Nakagawa K
    Clin Lung Cancer; 2016 Nov; 17(6):528-534. PubMed ID: 27318655
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Alectinib in the treatment of ALK-positive metastatic non-small cell lung cancer: clinical trial evidence and experience with a focus on brain metastases.
    Tomasini P; Egea J; Souquet-Bressand M; Greillier L; Barlesi F
    Ther Adv Respir Dis; 2019; 13():1753466619831906. PubMed ID: 30786826
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rapid and dramatic response to alectinib in an anaplastic lymphoma kinase rearranged non-small-cell lung cancer patient who is critically ill.
    Yoshida T; Hida T; Yatabe Y
    Anticancer Drugs; 2016 Jul; 27(6):573-5. PubMed ID: 26938871
    [TBL] [Abstract][Full Text] [Related]  

  • 38. ALK inhibitors for non-small cell lung cancer: A systematic review and network meta-analysis.
    Elliott J; Bai Z; Hsieh SC; Kelly SE; Chen L; Skidmore B; Yousef S; Zheng C; Stewart DJ; Wells GA
    PLoS One; 2020; 15(2):e0229179. PubMed ID: 32074131
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Overexpression of CD 133 and BCL-2 in non-small cell lung cancer with neuroendocrine differentiation after transformation in ALK rearrangement-positive adenocarcinoma.
    Koyama K; Katsurada N; Jimbo N; Tachihara M; Tamura D; Nakata K; Nagano T; Yamamoto M; Kamiryo H; Kobayashi K; Itoh T; Nishimura Y
    Pathol Int; 2019 May; 69(5):294-299. PubMed ID: 30900377
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Two cases of marked red cell anisopoikilocytosis and haemolysis with alectinib, an anaplastic lymphoma kinase inhibitor.
    Yuan Y; Mapp S; Xu W
    Br J Haematol; 2020 Sep; 190(5):642. PubMed ID: 32537738
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.